PLoS One:中国急性缺血性卒中患者静脉溶栓延迟的相关因素

2015-11-21 phylis 译 MedSci原创

住院延迟减少急性缺血性卒中(AIS)患者静脉溶栓(IVT)的效益,而在中国住院延迟的因素尚不清楚。研究者旨在通过医院队列研究,确定住院延迟相关的特定因素。住院延迟的定义为(入院到用药)DTN时间≥60min(标准延迟标准)或超过所有DTN的75%百分位数(严重延迟的标准)。获得受试者人口学资料,时间间隔(症状开始到入院时间OTD),DTN,及入院到检查时间(DTE),入院到影像学检查时间(DTI)

住院延迟减少急性缺血性卒中(AIS)患者静脉溶栓(IVT)的效益,而,中国住院延迟的因素尚不清楚。研究者旨在通过医院队列研究,确定住院延迟相关的特定因素。

住院延迟的定义为(入院到用药)DTN时间≥60min(标准延迟标准)或超过所有DTN的75%百分位数(严重延迟的标准)。获得受试者人口学资料、时间间隔(症状开始到入院时间OTD)、DTN、及入院到检查时间(DTE)、入院到影像学检查时间(DTI)、入院到实验室检查的时间(DTL)及最终检测到用药时间(FTN,获得影像学结果到用药时间)、病史及其他变量。应用Mann-Whitney U或Pearon Chi-Square 检验对上述变量进行组间比较,应用多变量线性回归分析确定住院延迟的独立变量。

共招募202名静脉溶栓患者。年龄的中位数为61岁,25.2%为女性。DTN(严重延迟标准)的较高百分位数为135min。与没有住院延迟的对照组相比,标准延迟标准组患者高龄、 OTD较短及转诊患者较少;严重延迟组患者男性,TIA患者或症状快速改善,多模式CT成像检查更常见。多变量线性回归分析,FTN和DTL与标准延迟显著相关,而DTE(P = 0.005)、DTI(P = 0.033)、DTL及FTN和严重延迟呈正相关。研究期间,DTNs趋势没有显著改变。

中国住院延迟原因是多方面的,决策过程及实验室检查对住院延迟影响最大。减少延迟的努力应集中在优化筛选检查及改进组织途径上。

原文出处:

Huang Q, Ma QF, Feng J, et al. Factors Associated with In-Hospital Delay in Intravenous Thrombolysis for Acute Ischemic Stroke: Lessons from China. PLoS One . 2015, Nov 17.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-01-24 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2010336, encodeId=f54d201033602, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Fri Feb 19 02:26:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806050, encodeId=d7f81806050df, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jul 02 00:26:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892705, encodeId=ff381892e0577, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Sep 21 21:26:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697278, encodeId=75f2169e278f6, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun Jan 24 15:26:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789737, encodeId=d72d1e89737dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Sep 07 15:26:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720078, encodeId=da7d1e200784b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Aug 03 19:26:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457446, encodeId=4df1145e44657, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 23 06:26:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]

相关资讯

Neurology:韩国轻中度饮酒可降低缺血性卒中的发生

目的:研究者进行了一项基于人群的病例对照研究,研究与西方酒精饮料偏好不同的韩国人在酒精摄入和缺血性卒中风险之间剂量反应关系,并且检测性别和缺血性卒中类型的影响。 方法:招募了年龄20岁以上首发卒中的患者1848名作为病例组。按照年龄(±3岁),性别及教育程度从第四和第五次韩国国家和营养调查中选取3589名无卒中的对照者与对照组进行配对。所有的受试者完成一项关于酒精摄入的结构性问卷调查的面谈。结果:

Stroke:血浆D-二聚体浓度高,小心缺血性卒中!

流行病学研究已经证实,D-二聚体,纤维蛋白降解产物,是冠心病的危险标志物,但是对于中风的前瞻性数据是有限的。由于血栓形成是许多卒中发生的关键机制,因此研究人员在ARIC试验中研究了是否D-二聚体是缺血性卒中发生的危险标志物。研究人员在1992年至1995年测量11415例ARIC患者的D-二聚体,他们没有卒中和冠状动脉心脏疾病。随后研究人员跟踪调查了他们卒中,卒中亚型,和冠状动脉心脏疾病事件直至2

J Neurochem:区分缺血性卒中和出血性卒中的生物标记物:RBP4 和GFAP

快速区分急性缺血性脑卒中和出血性脑卒中是非常必要的,能够促进改善预后。研究者旨在识别新型的生物标记物区分卒中亚型,并比较其他已经描述过的生物标记物的诊断能力。应用177抗体库筛选缺血性脑卒中(36)和出血性卒中(10)患者的血浆样本,其中有11种在不同脑卒中亚型中,浓度不同,主要是趋化因子、生长因子和血管生成因子。从16名缺血性卒中和16出血性卒中患者中选出五种蛋白,及视黄醇结合蛋白4(RPB4)

EUR J NEUROL:缺血性卒中患者容易出现视力问题

长期随访发现有1/4的脑梗死患者报告脑梗死后出现视力问题。脑梗死后出现视力问题降低患者的生活质量,增加患者因脑梗死致残率。对于脑梗死后出现视力问题的患者,全面的诊断评估和有针对性的康复治疗是非常重要的。

PLoS One:天津农村地区卒中发生率及卒中类型的调查(1992-2012)

背景:在中国城市中缺血性卒中发生增加,出血性卒中发生下降;然而, 在农村地区的趋势尚不清楚。研究者旨在探索中国农村地区卒中的发生率及卒中类型的改变得趋势。方法:通过人群为基础的卒中调查的天津大脑研究。从1985年共有14538名居民在天津乡冀县。研究者调查年龄标准化的卒中发生率(性别特异,类型特异及年龄特异),因为该地区1992年可用神经影像学检查,记录1992-1998, 1999-2005及2

JAMA Neurol:静脉溶栓前接受抗血小板治疗的患者,颅内出血发生率较高,但预后较好

重要性:静脉组织纤溶酶原激活物(tPA)治疗可改善缺血性卒中的预后;然而,许多患者在急性缺血性卒中前接受了抗血小板治疗,当进行tPA治疗时可能会增加出血的风险。目的:评估进行静脉tPA治疗的缺血性卒中患者在卒中前接受抗血小板治疗患者的风险和收益。设计:这项观察性研究应用美国心脏病协会,美国卒中协会获得指南卒中登记的数据,2009年1月到2015年3月31期间,在1545注册医院中接受tPA治疗的缺